Immunoassay Market [Technology (Enzyme, Fluorescent, Chemiluminescence, Radioimmunoassay), Analyzers & Reagents, Applications (Infectious Diseases, Cancer, Endocrinology, Cardiology), End Users (Hospitals, Laboratory, Academics)] – Global Forecast to 2018
Immunoassay have evolved as an integral part of the modern medical care practice owing to the continuous technological advancements in this field, the increase in healthcare awareness among people, and the increasing use of immunoassay tests in diagnosis and monitoring.
This research report categorizes the global on the basis of technology, application, product (analyzers and reagents), and end user. On the basis of technology, the enzyme immunoassay segment accounted for the largest share of the global market in 2012. Long-term presence in the market, high sensitivity for infectious/viral disease testing, and the huge demand from developing countries due to the lower costs of enzyme immunoassay in comparison to chemiluminescence immunoassay (CLIA) are all factors that are responsible for its growing share in the market. On the basis of product, the reagents market accounted for the largest share of this market in 2012. The accessibility of a wide range of reagents and the need for reliable, specific, and faster detection of chronic diseases at early stages are factors that are expected to drive the immunoassay reagents market.
The infectious diseases segment in the market is a high-volume, high-growth rate market. Major players such as Roche Diagnostics, Ortho Clinical Diagnostics (J&J), and bioMerieux are continuously launching new product models in order to gain a competitive edge in the infectious diseases segment, primarily because of the high immunoassay penetration rate in this segment.
Geographically, the Americas commanded the largest market share of the global market, followed by Europe. The factors driving the growth of the market in these geographies are the well-established diagnostic infrastructure, aging population, and rising acceptance of personalized medicine. However, on the other hand, the economic downturn and cuts in healthcare budgets are hampering the growth of the market. Countries like China, India, Australia, and Brazil will be major contributors of the growth of the market in the future. This market in China is poised to grow at a CAGR of 15.6% from 2013 to 2018. Increasing investments by leading companies in these immature markets, rising public awareness about personal health, and improving healthcare infrastructure in these regions are driving the growth of the market.
The deviations and the overlap of revenues between the various segments, especially in applications quoted in a number of sources was the major challenge faced while estimating the market size. This challenge was overcome by validating the data through a large number of industry experts and key opinion leaders.
From an insight perspective, this research report focuses on the qualitative data, market size, share, and growth of various segments and sub-segments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis, such as market dynamics (drivers, restraints, opportunities, and threats), value chain, PESTEL analysis, porters five forces analysis, regulations, and reimbursement challenges. The report also offers market shares, sizes, and related growth of various segments of the industry. It also focuses on the emerging and high-growth segments of immunoassay (enzyme and chemiluminescence immunoassay), emerging technologies, high-growth regions, countries, and the initiatives of their respective governments.
The competitive landscape covers the growth strategies adapted by the industry players in the last three years. The company profiles comprise of the basic views on the key players in the market and the product portfolios, developments, and strategies adopted to maintain and grow their market shares in the near future. The above mentioned market research data, current market size, and forecast of future trends will help the key players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, R&D investments for innovation in the products and technologies, and levels of output in order to remain successful.
Scope of the report
This research report categorizes the global market on the basis of technology, application, product (analyzers and reagents), and end user. These markets are broken down into segments and sub-segments, providing exhaustive value analysis for 2011, 2012, and 2013 as well as forecasts up to 2018. Each segment of the market is comprehensively analyzed at a granular level, by geography (Americas, Europe, APAC, and the Rest of the World), to provide in-depth information on the global scenario.
The global immunoassay market is segmented as follows:
This research report categorizes the global on the basis of technology, application, product (analyzers and reagents), and end user. On the basis of technology, the enzyme immunoassay segment accounted for the largest share of the global market in 2012. Long-term presence in the market, high sensitivity for infectious/viral disease testing, and the huge demand from developing countries due to the lower costs of enzyme immunoassay in comparison to chemiluminescence immunoassay (CLIA) are all factors that are responsible for its growing share in the market. On the basis of product, the reagents market accounted for the largest share of this market in 2012. The accessibility of a wide range of reagents and the need for reliable, specific, and faster detection of chronic diseases at early stages are factors that are expected to drive the immunoassay reagents market.
The infectious diseases segment in the market is a high-volume, high-growth rate market. Major players such as Roche Diagnostics, Ortho Clinical Diagnostics (J&J), and bioMerieux are continuously launching new product models in order to gain a competitive edge in the infectious diseases segment, primarily because of the high immunoassay penetration rate in this segment.
Geographically, the Americas commanded the largest market share of the global market, followed by Europe. The factors driving the growth of the market in these geographies are the well-established diagnostic infrastructure, aging population, and rising acceptance of personalized medicine. However, on the other hand, the economic downturn and cuts in healthcare budgets are hampering the growth of the market. Countries like China, India, Australia, and Brazil will be major contributors of the growth of the market in the future. This market in China is poised to grow at a CAGR of 15.6% from 2013 to 2018. Increasing investments by leading companies in these immature markets, rising public awareness about personal health, and improving healthcare infrastructure in these regions are driving the growth of the market.
The deviations and the overlap of revenues between the various segments, especially in applications quoted in a number of sources was the major challenge faced while estimating the market size. This challenge was overcome by validating the data through a large number of industry experts and key opinion leaders.
From an insight perspective, this research report focuses on the qualitative data, market size, share, and growth of various segments and sub-segments, competitive landscape, and company profiles. The qualitative data covers various levels of industry analysis, such as market dynamics (drivers, restraints, opportunities, and threats), value chain, PESTEL analysis, porters five forces analysis, regulations, and reimbursement challenges. The report also offers market shares, sizes, and related growth of various segments of the industry. It also focuses on the emerging and high-growth segments of immunoassay (enzyme and chemiluminescence immunoassay), emerging technologies, high-growth regions, countries, and the initiatives of their respective governments.
The competitive landscape covers the growth strategies adapted by the industry players in the last three years. The company profiles comprise of the basic views on the key players in the market and the product portfolios, developments, and strategies adopted to maintain and grow their market shares in the near future. The above mentioned market research data, current market size, and forecast of future trends will help the key players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, R&D investments for innovation in the products and technologies, and levels of output in order to remain successful.
Scope of the report
This research report categorizes the global market on the basis of technology, application, product (analyzers and reagents), and end user. These markets are broken down into segments and sub-segments, providing exhaustive value analysis for 2011, 2012, and 2013 as well as forecasts up to 2018. Each segment of the market is comprehensively analyzed at a granular level, by geography (Americas, Europe, APAC, and the Rest of the World), to provide in-depth information on the global scenario.
The global immunoassay market is segmented as follows:
- By Technology:
- Enzyme Immunoassay (EIA)
- Fluorescent Immunoassay
- Chemiluminescence Immunoassay (CLIA)
- Radioimmunoassays (RIA)
- Others (Nephelometric Immunoassay, Turbidimetric Immunoassay, and Counting Immunoassay (CIA))
- By Application:
- Oncology
- Infectious Diseases
- Cardiology
- Bone and Mineral
- Endocrinology
- Autoimmunity
- Toxicology
- Hematology (Anemia)
- Neonatal Screening
- Others
- By Product:
- Analyzers
- High-throughput
- Medium-throughput
- Low-throughput
- Reagents
- By End User:
- Hospitals (Private and Public)
- Laboratories (Private and Public)
- Academics
- Pharmaceutical Industry, CROs, and Biotechs
- Others
- By Geography:
- Americas
- U.S.
- Canada
- Brazil
- Mexico
- RoA (Rest of Americas)
- Europe
- Germany
- France
- U.K.
- Spain
- Italy
- RoE (Rest of Europe)
- Asia-Pacific
- Japan
- China
- India
- South Korea
- RoAP (Rest of Asia-Pacific)
- RoW (Rest of World) (Middle East and Africa)
1 INTRODUCTION
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 RESEARCH METHODOLOGY
1.3.1 SECONDARY SOURCES
1.3.2 PRIMARY SOURCES
1.3.3 MARKET SIZE ESTIMATION
1.3.4 MARKET SHARE
1.3.5 KEY DATA POINTS FROM SECONDARY SOURCES
1.3.6 KEY DATA POINTS FROM PRIMARY SOURCES
1.3.7 ASSUMPTIONS
1.4 MARKETS COVERED
1.5 STAKEHOLDERS
1.6 MARKET SCOPE
2 EXECUTIVE SUMMARY
3 PREMIUM INSIGHTS
3.1 IMMUNOASSAY MARKET VS OTHER IVD MARKET SEGMENTS
3.2 GEOGRAPHIC ANALYSIS, BY COUNTRY
3.3 APPLICATIONS MARKET
3.4 END-USER ANALYSIS
3.5 COMPETITIVE ANALYSIS
4 INDUSTRY ANALYSIS & MARKET OVERVIEW
4.1 INTRODUCTION
4.2 EVOLUTION
4.3 MARKET SEGMENTATION
4.4 MARKET DYNAMICS
4.4.1 DRIVERS
4.4.1.1 Rising incidence of chronic and infectious diseases in emerging economies to drive the immunoassays market
4.4.1.2 Rapidly aging population will result in increasing chronic diseases
4.4.1.3 Growing popularity of portable immunoassays to stimulate growth
4.4.1.4 Novel biomarkers and innovative technologies to give an edge to immunoassay companies
4.4.1.5 Sensitive, cost-effective, & rapidness of immunoassays increases adoption rates
4.4.1.6 Increasing health awareness responsible for the growth of the immunoassays market
4.4.2 RESTRAINTS
4.4.2.1 Low detection limits restrict adoption of immunoassay tests
4.4.2.2 Lack of budget to restrict growth
4.4.3 OPPORTUNITIES
4.4.3.1 New range of condition-specific markers and tests with advances in genomics and proteomics
4.4.3.2 Increasing adoption in emerging markets such as China and India are creating growth opportunities for the immunoassays market
4.4.4 THREATS
4.4.4.1 Pricing pressure for some tests due to competition from lower cost-per-test technologies
4.4.4.2 Stringent regulatory framework acts as a major challenge
4.5 BURNING ISSUES
4.5.1 LATERAL FLOW IMMUNOASSAYS
4.5.1.1 Demand for LF tests on the rise
4.5.2 LABORATORY AUTOMATION FOR INCREASED EFFICIENCY AND ACCURATE DIAGNOSIS
4.6 TECHNIQUES TO VALIDATE NEW BIOMARKERS USING IMMUNOASSAYS
4.7 REGULATIONS
4.7.1 U.S.
4.7.2 EUROPE
4.7.3 JAPAN
4.7.4 CHINA
4.7.5 INDIA
4.8 REIMBURSEMENT SCENARIO & CHALLENGES
4.9 VALUE CHAIN ANALYSIS
4.10 PORTER’S ANALYSIS
4.10.1 THREAT FROM NEW ENTRANTS
4.10.2 THREAT FROM SUBSTITUTES
4.10.3 BARGAINING POWER OF BUYERS
4.10.4 BARGAINING POWER OF SUPPLIERS
4.10.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
4.11 PESTEL ANALYSIS
4.11.1 POLITICAL
4.11.2 ECONOMIC
4.11.3 SOCIO-CULTURAL
4.11.4 TECHNOLOGICAL
4.11.5 ENVIRONMENTAL
4.11.6 LEGAL
4.12 MARKET SHARE ANALYSIS
4.12.1 GLOBAL
4.12.2 AMERICAS
4.12.3 EUROPE
4.12.4 ASIA-PACIFIC
5 IMMUNOASSAYS MARKET, BY TECHNOLOGY
5.1 INTRODUCTION
5.2 ENZYME IMMUNOASSAYS (EIA)
5.2.1 EIA IS THE MOST PREFERRED TECHNIQUE IN THE IMMUNOASSAY MARKET
5.3 FLUORESCENCE IMMUNOASSAYS (FIA)
5.3.1 SENSITIVITY ALONG WITH LOW COST OF FIA DRIVES THE MARKET
5.4 CHEMILUMINESCENCE IMMUNOASSAYS (CLIA)
5.4.1 HIGH SENSITIVITY, AUTOMATION & WIDE APPLICATIONS OF CLIA RESPONSIBLE FOR THE HIGHEST GROWTH
5.5 RADIOIMMUNOASSAYS (RIA)
5.5.1 DESPITE WIDE APPLICATIONS & HIGH SENSITIVITY, RIA TO LOSE SHARE TO SAFER TECHNOLOGIES LIKE EIA & CLIA
5.6 OTHERS [NEPHELOMETRY, TURBIDIMETRY, & COUNTING IMMUNOASSAYS (CIA)]
5.6.1 NEPHELOMETRY WILL GROW AT A MEAGER PACE DUE TO LACK OF MAJOR ADVANCEMENTS
5.6.2 TURBIDOMETRY & CIA TO GROW AT A DECENT RATE
5.7 THE IMMUNOASSAYS MARKET VS. OTHER IVD SEGMENTS
5.7.1 IMMUNOASSAYS CONTRIBUTE THE HIGHEST TO IVD MARKET; MOLECULAR DIAGNOSTICS SEGMENT WILL GROW THE FASTEST
6 IMMUNOASSAYS MARKET, BY PRODUCTS
(ANALYZERS & REAGENTS)
6.1 INTRODUCTION
6.1.1 REAGENTS MARKET TO GROW WITH INCREASE IN TEST VOLUMES
6.2 ANALYZERS
6.2.1 MEDIUM-THROUGHPUT ANALYZERS CONTRIBUTE THE HIGHEST TO THE ANALYZERS REVENUE
6.2.2 HIGH-THROUGHPUT ANALYZERS
6.2.2.1 High throughput analyzers will witness the fastest growth
6.2.3 MEDIUM-THROUGHPUT ANALYZERS
6.2.4 LOW-THROUGHPUT ANALYZERS
6.3 REAGENTS
6.3.1 HOME BREW ASSAYS ARE SUBJECT TO LENIENT REGULATIONS
7 IMMUNOASSAY MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 ONCOLOGY
7.2.1 ONCOLOGY BIOMARKERS CAN HELP EARLY DETECTION OF CANCERS
7.3 ENDOCRINOLOGY
7.3.1 ENDOCRINOLOGY SEGMENT WILL BE DRIVEN BY INCREASING INCIDENCES OF DIABETES & THYROID DISORDERS
7.4 BONE & MINERAL
7.4.1 INCREASING PREVALENCE OF BONE & MINERAL DISORDERS TO PROPEL THE IMMUNOASSAY MARKET
7.5 CARDIOLOGY
7.5.1 IMMUNOASSAY TECHNIQUES ARE FREQUENTLY USED FOR DIAGNOSIS OF CARDIAC AILMENTS
7.5.2 TROPONIN IS THE MOST PREFERRED BIOMARKER IN CARDIOLOGY
7.6 INFECTIOUS DISEASES
7.6.1 INCREASING INVESTMENTS IN THE INFECTIOUS DISEASES DUE TO HIGH-SHARE, HIGH-GROWTH RATE NATURE OF THE SEGMENT
7.7 HEMATOLOGY
7.8 AUTOIMMUNITY
7.8.1 AUTOIMMUNITY SEGMENT PROVIDES SIGNIFICANT GROWTH OPPORTUNITIES TO IMMUNOASSAY PLAYERS
7.9 TOXICOLOGY
7.9.1 INCREASING DRUG-ABUSE CASES TO BOOST IMMUNOASSAY TOXICOLOGY MARKET
7.10 NEONATAL SCREENING
7.10.1 NOVEL BIOMARKERS IDENTIFIED FOR NEWBORN SCREENING IN PUBLIC HEALTH PRACTICES
7.11 OTHERS (ALLERGY, STOOL TESTING, & SEROLOGY)
8 GLOBAL IMMUNOASSAYS MARKET, BY END-USERS
8.1 INTRODUCTION
8.2 HOSPITALS (PRIVATE/PUBLIC)
8.2.1 HOSPITALS AS END-USERS IS A HIGH GROWTH RATE, HIGH MARKET SIZE SEGMENT
8.3 LABORATORIES (PRIVATE/PUBLIC)
8.3.1 LABORATORIES OFFER VARIOUS ADVANTAGES OVER HOSPITALS YET WILL GROW AT LOWER RATE DUE TO SMALLER VOLUMES
8.4 ACADEMICS
8.5 PHARMACEUTICAL INDUSTRY, CROS, & BIOTECHS
8.5.1 INCREASING RESEARCH ACTIVITIES TO DRIVE THE INDUSTRIAL SEGMENT
8.6 OTHERS (PHYSICIANS’ OFFICES, BLOOD BANKS, PATIENT SELF-TESTING, & AMBULATORY CENTERS)
8.6.1 THE DEMAND FOR PST IS ON A RISE
9 GEOGRAPHIC ANALYSIS
9.1 INTRODUCTION
9.1.1 U.S. THE MAJOR CONTRIBUTOR TO IMMUNOASSAY OWING TO TECHNOLOGICAL ADVANCEMENTS & GOVERNMENT SUPPORT
9.1.2 ASIAN AND LATAM COUNTRIES OFFER HUGE OPPORTUNITIES TO INVESTORS
9.2 THE AMERICAS
9.2.1 U.S.
9.2.1.1 PPACA has a positive impact on immunoassay business
9.2.1.2 Despite unfavorable conditions key players look to consolidate their business in U.S.
9.2.2 CANADA
9.2.3 MEXICO
9.2.3.1 Government regulations & reforms support the growth of immunoassay in Mexico
9.2.4 BRAZIL
9.2.4.1 Healthcare reforms, government initiatives & rise of infectious diseases to drive the Brazilian immunoassay market
9.2.5 REST OF AMERICAS (ROA)
9.3 EUROPE
9.3.1 EUROPE IMMUNOASSAY MARKET WILL GROW AT A SLOW PACE DUE TO DECREASED FUNDING & STRICT REGULATORY GUIDELINES
9.3.2 GERMANY
9.3.2.1 Germany to grow at a high pace due to presence of defined outsourcing chain of laboratory services & government support
9.3.3 FRANCE
9.3.3.1 France is the second biggest immunoassay market in Europe
9.3.4 ITALY
9.3.4.1 Italy will grow at a decent pace despite various challenges
9.3.5 SPAIN
9.3.5.1 Spain to grow at a meager pace due to budget cuts and late payments
9.3.6 U.K.
9.3.6.1 U.K.to grow at the fastest rate in Europe despite roadblocks
9.3.7 REST OF EUROPE (ROE)
9.4 ASIA-PACIFIC
9.4.1 JAPAN
9.4.1.1 Japanese immunoassay market to grow the slowest in Asia due to regulatory issues & diagnostic lag
9.4.2 INDIA
9.4.2.1 Large population base, increased affordability & government initiatives drive the Indian immunoassay market
9.4.3 CHINA
9.4.3.1 China will be the fastest growing immunoassay market, globally
9.4.4 SOUTH KOREA
9.4.4.1 South Korea to witness double-digit growth in the immunoassay arena
9.4.5 TAIWAN
9.4.5.1 Taiwan to grow at brisk pace in the immunoassay business
9.4.6 ROAP
9.5 REST OF THE WORLD (ROW)
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.1.1 AGREEMENTS, PARTNERSHIPS & JVS IS THE KEY GROWTH STRATEGY ADOPTED BY PLAYERS
10.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, & JOINT VENTURES
10.3 NEW PRODUCT LAUNCHES
10.4 MERGERS & ACQUISITIONS
10.5 OTHER DEVELOPMENTS
11 COMPANY PROFILES(OVERVIEW, FINANCIALS, PRODUCTS & SERVICES, STRATEGY, & DEVELOPMENTS)
11.1 ABBOTT LABORATORIES, INC.
11.2 ALERE, INC.
11.3 BECTON, DICKINSON AND COMPANY
11.4 BIOMERIEUX
11.5 DANAHER CORPORATION (BECKMAN COULTER)
11.6 DIASORIN S.P.A
11.7 DIASOURCE IMMUNOASSAYS S.A.
11.8 DRG INTERNATIONAL, INC.
11.9 HOLOGIC (GEN-PROBE )
11.10 IBL INTERNATIONAL GMBH
11.11 IDS PLC
11.12 MERIDIAN LIFE SCIENCE, INC.
11.13 ORTHO CLINICAL DIAGNOSTICS (A J&J COMPANY)
11.14 QIAGEN N.V.
11.15 ROCHE DIAGNOSTICS LIMITED
11.16 SIEMENS HEALTHCARE
11.17 SYSMEX CORPORATION
11.18 THERMO FISHER SCIENTIFIC, INC. (BRAHMS)(Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.)
12 APPENDIX
1.1 KEY TAKE-AWAYS
1.2 REPORT DESCRIPTION
1.3 RESEARCH METHODOLOGY
1.3.1 SECONDARY SOURCES
1.3.2 PRIMARY SOURCES
1.3.3 MARKET SIZE ESTIMATION
1.3.4 MARKET SHARE
1.3.5 KEY DATA POINTS FROM SECONDARY SOURCES
1.3.6 KEY DATA POINTS FROM PRIMARY SOURCES
1.3.7 ASSUMPTIONS
1.4 MARKETS COVERED
1.5 STAKEHOLDERS
1.6 MARKET SCOPE
2 EXECUTIVE SUMMARY
3 PREMIUM INSIGHTS
3.1 IMMUNOASSAY MARKET VS OTHER IVD MARKET SEGMENTS
3.2 GEOGRAPHIC ANALYSIS, BY COUNTRY
3.3 APPLICATIONS MARKET
3.4 END-USER ANALYSIS
3.5 COMPETITIVE ANALYSIS
4 INDUSTRY ANALYSIS & MARKET OVERVIEW
4.1 INTRODUCTION
4.2 EVOLUTION
4.3 MARKET SEGMENTATION
4.4 MARKET DYNAMICS
4.4.1 DRIVERS
4.4.1.1 Rising incidence of chronic and infectious diseases in emerging economies to drive the immunoassays market
4.4.1.2 Rapidly aging population will result in increasing chronic diseases
4.4.1.3 Growing popularity of portable immunoassays to stimulate growth
4.4.1.4 Novel biomarkers and innovative technologies to give an edge to immunoassay companies
4.4.1.5 Sensitive, cost-effective, & rapidness of immunoassays increases adoption rates
4.4.1.6 Increasing health awareness responsible for the growth of the immunoassays market
4.4.2 RESTRAINTS
4.4.2.1 Low detection limits restrict adoption of immunoassay tests
4.4.2.2 Lack of budget to restrict growth
4.4.3 OPPORTUNITIES
4.4.3.1 New range of condition-specific markers and tests with advances in genomics and proteomics
4.4.3.2 Increasing adoption in emerging markets such as China and India are creating growth opportunities for the immunoassays market
4.4.4 THREATS
4.4.4.1 Pricing pressure for some tests due to competition from lower cost-per-test technologies
4.4.4.2 Stringent regulatory framework acts as a major challenge
4.5 BURNING ISSUES
4.5.1 LATERAL FLOW IMMUNOASSAYS
4.5.1.1 Demand for LF tests on the rise
4.5.2 LABORATORY AUTOMATION FOR INCREASED EFFICIENCY AND ACCURATE DIAGNOSIS
4.6 TECHNIQUES TO VALIDATE NEW BIOMARKERS USING IMMUNOASSAYS
4.7 REGULATIONS
4.7.1 U.S.
4.7.2 EUROPE
4.7.3 JAPAN
4.7.4 CHINA
4.7.5 INDIA
4.8 REIMBURSEMENT SCENARIO & CHALLENGES
4.9 VALUE CHAIN ANALYSIS
4.10 PORTER’S ANALYSIS
4.10.1 THREAT FROM NEW ENTRANTS
4.10.2 THREAT FROM SUBSTITUTES
4.10.3 BARGAINING POWER OF BUYERS
4.10.4 BARGAINING POWER OF SUPPLIERS
4.10.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
4.11 PESTEL ANALYSIS
4.11.1 POLITICAL
4.11.2 ECONOMIC
4.11.3 SOCIO-CULTURAL
4.11.4 TECHNOLOGICAL
4.11.5 ENVIRONMENTAL
4.11.6 LEGAL
4.12 MARKET SHARE ANALYSIS
4.12.1 GLOBAL
4.12.2 AMERICAS
4.12.3 EUROPE
4.12.4 ASIA-PACIFIC
5 IMMUNOASSAYS MARKET, BY TECHNOLOGY
5.1 INTRODUCTION
5.2 ENZYME IMMUNOASSAYS (EIA)
5.2.1 EIA IS THE MOST PREFERRED TECHNIQUE IN THE IMMUNOASSAY MARKET
5.3 FLUORESCENCE IMMUNOASSAYS (FIA)
5.3.1 SENSITIVITY ALONG WITH LOW COST OF FIA DRIVES THE MARKET
5.4 CHEMILUMINESCENCE IMMUNOASSAYS (CLIA)
5.4.1 HIGH SENSITIVITY, AUTOMATION & WIDE APPLICATIONS OF CLIA RESPONSIBLE FOR THE HIGHEST GROWTH
5.5 RADIOIMMUNOASSAYS (RIA)
5.5.1 DESPITE WIDE APPLICATIONS & HIGH SENSITIVITY, RIA TO LOSE SHARE TO SAFER TECHNOLOGIES LIKE EIA & CLIA
5.6 OTHERS [NEPHELOMETRY, TURBIDIMETRY, & COUNTING IMMUNOASSAYS (CIA)]
5.6.1 NEPHELOMETRY WILL GROW AT A MEAGER PACE DUE TO LACK OF MAJOR ADVANCEMENTS
5.6.2 TURBIDOMETRY & CIA TO GROW AT A DECENT RATE
5.7 THE IMMUNOASSAYS MARKET VS. OTHER IVD SEGMENTS
5.7.1 IMMUNOASSAYS CONTRIBUTE THE HIGHEST TO IVD MARKET; MOLECULAR DIAGNOSTICS SEGMENT WILL GROW THE FASTEST
6 IMMUNOASSAYS MARKET, BY PRODUCTS
(ANALYZERS & REAGENTS)
6.1 INTRODUCTION
6.1.1 REAGENTS MARKET TO GROW WITH INCREASE IN TEST VOLUMES
6.2 ANALYZERS
6.2.1 MEDIUM-THROUGHPUT ANALYZERS CONTRIBUTE THE HIGHEST TO THE ANALYZERS REVENUE
6.2.2 HIGH-THROUGHPUT ANALYZERS
6.2.2.1 High throughput analyzers will witness the fastest growth
6.2.3 MEDIUM-THROUGHPUT ANALYZERS
6.2.4 LOW-THROUGHPUT ANALYZERS
6.3 REAGENTS
6.3.1 HOME BREW ASSAYS ARE SUBJECT TO LENIENT REGULATIONS
7 IMMUNOASSAY MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 ONCOLOGY
7.2.1 ONCOLOGY BIOMARKERS CAN HELP EARLY DETECTION OF CANCERS
7.3 ENDOCRINOLOGY
7.3.1 ENDOCRINOLOGY SEGMENT WILL BE DRIVEN BY INCREASING INCIDENCES OF DIABETES & THYROID DISORDERS
7.4 BONE & MINERAL
7.4.1 INCREASING PREVALENCE OF BONE & MINERAL DISORDERS TO PROPEL THE IMMUNOASSAY MARKET
7.5 CARDIOLOGY
7.5.1 IMMUNOASSAY TECHNIQUES ARE FREQUENTLY USED FOR DIAGNOSIS OF CARDIAC AILMENTS
7.5.2 TROPONIN IS THE MOST PREFERRED BIOMARKER IN CARDIOLOGY
7.6 INFECTIOUS DISEASES
7.6.1 INCREASING INVESTMENTS IN THE INFECTIOUS DISEASES DUE TO HIGH-SHARE, HIGH-GROWTH RATE NATURE OF THE SEGMENT
7.7 HEMATOLOGY
7.8 AUTOIMMUNITY
7.8.1 AUTOIMMUNITY SEGMENT PROVIDES SIGNIFICANT GROWTH OPPORTUNITIES TO IMMUNOASSAY PLAYERS
7.9 TOXICOLOGY
7.9.1 INCREASING DRUG-ABUSE CASES TO BOOST IMMUNOASSAY TOXICOLOGY MARKET
7.10 NEONATAL SCREENING
7.10.1 NOVEL BIOMARKERS IDENTIFIED FOR NEWBORN SCREENING IN PUBLIC HEALTH PRACTICES
7.11 OTHERS (ALLERGY, STOOL TESTING, & SEROLOGY)
8 GLOBAL IMMUNOASSAYS MARKET, BY END-USERS
8.1 INTRODUCTION
8.2 HOSPITALS (PRIVATE/PUBLIC)
8.2.1 HOSPITALS AS END-USERS IS A HIGH GROWTH RATE, HIGH MARKET SIZE SEGMENT
8.3 LABORATORIES (PRIVATE/PUBLIC)
8.3.1 LABORATORIES OFFER VARIOUS ADVANTAGES OVER HOSPITALS YET WILL GROW AT LOWER RATE DUE TO SMALLER VOLUMES
8.4 ACADEMICS
8.5 PHARMACEUTICAL INDUSTRY, CROS, & BIOTECHS
8.5.1 INCREASING RESEARCH ACTIVITIES TO DRIVE THE INDUSTRIAL SEGMENT
8.6 OTHERS (PHYSICIANS’ OFFICES, BLOOD BANKS, PATIENT SELF-TESTING, & AMBULATORY CENTERS)
8.6.1 THE DEMAND FOR PST IS ON A RISE
9 GEOGRAPHIC ANALYSIS
9.1 INTRODUCTION
9.1.1 U.S. THE MAJOR CONTRIBUTOR TO IMMUNOASSAY OWING TO TECHNOLOGICAL ADVANCEMENTS & GOVERNMENT SUPPORT
9.1.2 ASIAN AND LATAM COUNTRIES OFFER HUGE OPPORTUNITIES TO INVESTORS
9.2 THE AMERICAS
9.2.1 U.S.
9.2.1.1 PPACA has a positive impact on immunoassay business
9.2.1.2 Despite unfavorable conditions key players look to consolidate their business in U.S.
9.2.2 CANADA
9.2.3 MEXICO
9.2.3.1 Government regulations & reforms support the growth of immunoassay in Mexico
9.2.4 BRAZIL
9.2.4.1 Healthcare reforms, government initiatives & rise of infectious diseases to drive the Brazilian immunoassay market
9.2.5 REST OF AMERICAS (ROA)
9.3 EUROPE
9.3.1 EUROPE IMMUNOASSAY MARKET WILL GROW AT A SLOW PACE DUE TO DECREASED FUNDING & STRICT REGULATORY GUIDELINES
9.3.2 GERMANY
9.3.2.1 Germany to grow at a high pace due to presence of defined outsourcing chain of laboratory services & government support
9.3.3 FRANCE
9.3.3.1 France is the second biggest immunoassay market in Europe
9.3.4 ITALY
9.3.4.1 Italy will grow at a decent pace despite various challenges
9.3.5 SPAIN
9.3.5.1 Spain to grow at a meager pace due to budget cuts and late payments
9.3.6 U.K.
9.3.6.1 U.K.to grow at the fastest rate in Europe despite roadblocks
9.3.7 REST OF EUROPE (ROE)
9.4 ASIA-PACIFIC
9.4.1 JAPAN
9.4.1.1 Japanese immunoassay market to grow the slowest in Asia due to regulatory issues & diagnostic lag
9.4.2 INDIA
9.4.2.1 Large population base, increased affordability & government initiatives drive the Indian immunoassay market
9.4.3 CHINA
9.4.3.1 China will be the fastest growing immunoassay market, globally
9.4.4 SOUTH KOREA
9.4.4.1 South Korea to witness double-digit growth in the immunoassay arena
9.4.5 TAIWAN
9.4.5.1 Taiwan to grow at brisk pace in the immunoassay business
9.4.6 ROAP
9.5 REST OF THE WORLD (ROW)
10 COMPETITIVE LANDSCAPE
10.1 INTRODUCTION
10.1.1 AGREEMENTS, PARTNERSHIPS & JVS IS THE KEY GROWTH STRATEGY ADOPTED BY PLAYERS
10.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, & JOINT VENTURES
10.3 NEW PRODUCT LAUNCHES
10.4 MERGERS & ACQUISITIONS
10.5 OTHER DEVELOPMENTS
11 COMPANY PROFILES(OVERVIEW, FINANCIALS, PRODUCTS & SERVICES, STRATEGY, & DEVELOPMENTS)
11.1 ABBOTT LABORATORIES, INC.
11.2 ALERE, INC.
11.3 BECTON, DICKINSON AND COMPANY
11.4 BIOMERIEUX
11.5 DANAHER CORPORATION (BECKMAN COULTER)
11.6 DIASORIN S.P.A
11.7 DIASOURCE IMMUNOASSAYS S.A.
11.8 DRG INTERNATIONAL, INC.
11.9 HOLOGIC (GEN-PROBE )
11.10 IBL INTERNATIONAL GMBH
11.11 IDS PLC
11.12 MERIDIAN LIFE SCIENCE, INC.
11.13 ORTHO CLINICAL DIAGNOSTICS (A J&J COMPANY)
11.14 QIAGEN N.V.
11.15 ROCHE DIAGNOSTICS LIMITED
11.16 SIEMENS HEALTHCARE
11.17 SYSMEX CORPORATION
11.18 THERMO FISHER SCIENTIFIC, INC. (BRAHMS)(Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.)
12 APPENDIX
LIST OF TABLES
TABLE 1 GLOBAL IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 2 ENZYME IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 3 AMERICAS: ENZYME IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 4 EUROPE: ENZYME IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 5 ASIA-PACIFIC: ENZYME IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 6 FLUORESCENT IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 7 AMERICAS: FLUORESCENT IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 8 EUROPE: FLUORESCENT IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 9 ASIA-PACIFIC: FLUORESCENT IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 10 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 11 AMERICAS: CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 12 EUROPE: CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 13 ASIA-PACIFIC: CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 14 RADIOIMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 15 AMERICAS: RADIOIMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 16 EUROPE: RADIOIMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 17 ASIA-PACIFIC: RADIOIMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 18 OTHER IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 19 AMERICAS: OTHER IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 20 EUROPE: OTHER IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 21 ASIA-PACIFIC: OTHER IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 22 GLOBAL IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2011 – 2018 ($MILLION)
TABLE 23 GLOBAL IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 24 GLOBAL: IMMUNOASSAY ANALYZER MARKET, BY THROUGHPUT, 2011 – 2018 ($MILLION)
TABLE 25 IMMUNOASSAY ANALYZERS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 26 AMERICAS: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 27 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 28 ASIA-PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 29 IMMUNOASSAY REAGENTS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 30 AMERICAS: IMMUNOASSAY REAGENTS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 31 EUROPE: IMMUNOASSAY REAGENTS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 32 ASIA-PACIFIC: IMMUNOASSAY REAGENTS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 33 GLOBAL IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 34 ONCOLOGY IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 35 ENDOCRINOLOGY IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 36 BONE & MINERAL IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 37 COMMONLY USED CARDIAC BIOMARKER TESTS
TABLE 38 CARDIAC BIOMARKER TESTS USED FOR PROGNOSIS
TABLE 39 CARDIOLOGY IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 40 INFECTIOUS DISEASES IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 41 HEMATOLOGY IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 42 AUTOIMMUNITY IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 43 TOXICOLOGY IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 44 NEONATAL SCREENING IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 45 OTHER IMMUNOASSAY APPLICATIONS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 46 GLOBAL IMMUNOASSAYS MARKET, BY END-USERS, 2011 – 2018 ($MILLION)
TABLE 47 IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 48 THE AMERICAS: IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 49 THE AMERICAS: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 50 AMERICAS: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 51 AMERICAS: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 52 U.S.: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 53 U.S.: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 54 U.S.: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 55 CANADA: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 56 CANADA: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 57 CANADA: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 58 MEXICO: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 59 MEXICO: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 60 MEXICO: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 61 BRAZIL: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 62 BRAZIL: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 63 BRAZIL: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 64 ROA: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 65 ROA: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 66 ROA: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 67 EUROPE: IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 68 EUROPE: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 69 EUROPE: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 70 EUROPE: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 71 GERMANY: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 72 GERMANY: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 73 GERMANY: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 74 FRANCE: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 75 FRANCE: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 76 FRANCE: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 77 ITALY: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 78 ITALY: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 79 ITALY: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 80 SPAIN: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 81 SPAIN: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 82 SPAIN: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 83 U.K.: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 84 U.K.: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 85 U.K.: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 86 ROE: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 87 ROE: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 88 ROE: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 89 ASIA-PACIFIC: IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 90 ASIA-PACIFIC: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 91 ASIA-PACIFIC: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 92 ASIA-PACIFIC: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 93 JAPAN: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 94 JAPAN: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 95 JAPAN: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 96 INDIA: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 97 INDIA: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 98 INDIA: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 99 CHINA: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 100 CHINA: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 101 CHINA: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 102 SOUTH KOREA: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 103 SOUTH KOREA: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 104 SOUTH KOREA: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 105 TAIWAN: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 106 TAIWAN: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 107 TAIWAN: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 108 ROAP: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 109 ROAP: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 110 ROAP: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 111 ROW: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 112 ROW: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 113 ROW: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 114 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, & JOINT VENTURES (2010 – 2013)
TABLE 115 NEW PRODUCT LAUNCHES (2010 – 2013)
TABLE 116 MERGERS & ACQUISITIONS (2010 – 2013)
TABLE 117 OTHER DEVELOPMENTS (2011 – 2013)
TABLE 118 APPENDIX: OTHER DEVELOPMENTS (2010 – 2013)
TABLE 1 GLOBAL IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 2 ENZYME IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 3 AMERICAS: ENZYME IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 4 EUROPE: ENZYME IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 5 ASIA-PACIFIC: ENZYME IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 6 FLUORESCENT IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 7 AMERICAS: FLUORESCENT IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 8 EUROPE: FLUORESCENT IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 9 ASIA-PACIFIC: FLUORESCENT IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 10 CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 11 AMERICAS: CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 12 EUROPE: CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 13 ASIA-PACIFIC: CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 14 RADIOIMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 15 AMERICAS: RADIOIMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 16 EUROPE: RADIOIMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 17 ASIA-PACIFIC: RADIOIMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 18 OTHER IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 19 AMERICAS: OTHER IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 20 EUROPE: OTHER IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 21 ASIA-PACIFIC: OTHER IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 22 GLOBAL IN VITRO DIAGNOSTICS MARKET, BY TECHNIQUE, 2011 – 2018 ($MILLION)
TABLE 23 GLOBAL IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 24 GLOBAL: IMMUNOASSAY ANALYZER MARKET, BY THROUGHPUT, 2011 – 2018 ($MILLION)
TABLE 25 IMMUNOASSAY ANALYZERS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 26 AMERICAS: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 27 EUROPE: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 28 ASIA-PACIFIC: IMMUNOASSAY ANALYZERS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 29 IMMUNOASSAY REAGENTS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 30 AMERICAS: IMMUNOASSAY REAGENTS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 31 EUROPE: IMMUNOASSAY REAGENTS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 32 ASIA-PACIFIC: IMMUNOASSAY REAGENTS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 33 GLOBAL IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 34 ONCOLOGY IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 35 ENDOCRINOLOGY IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 36 BONE & MINERAL IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 37 COMMONLY USED CARDIAC BIOMARKER TESTS
TABLE 38 CARDIAC BIOMARKER TESTS USED FOR PROGNOSIS
TABLE 39 CARDIOLOGY IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 40 INFECTIOUS DISEASES IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 41 HEMATOLOGY IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 42 AUTOIMMUNITY IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 43 TOXICOLOGY IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 44 NEONATAL SCREENING IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 45 OTHER IMMUNOASSAY APPLICATIONS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 46 GLOBAL IMMUNOASSAYS MARKET, BY END-USERS, 2011 – 2018 ($MILLION)
TABLE 47 IMMUNOASSAYS MARKET, BY GEOGRAPHY, 2011 – 2018 ($MILLION)
TABLE 48 THE AMERICAS: IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 49 THE AMERICAS: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 50 AMERICAS: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 51 AMERICAS: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 52 U.S.: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 53 U.S.: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 54 U.S.: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 55 CANADA: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 56 CANADA: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 57 CANADA: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 58 MEXICO: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 59 MEXICO: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 60 MEXICO: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 61 BRAZIL: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 62 BRAZIL: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 63 BRAZIL: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 64 ROA: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 65 ROA: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 66 ROA: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 67 EUROPE: IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 68 EUROPE: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 69 EUROPE: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 70 EUROPE: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 71 GERMANY: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 72 GERMANY: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 73 GERMANY: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 74 FRANCE: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 75 FRANCE: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 76 FRANCE: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 77 ITALY: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 78 ITALY: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 79 ITALY: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 80 SPAIN: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 81 SPAIN: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 82 SPAIN: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 83 U.K.: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 84 U.K.: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 85 U.K.: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 86 ROE: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 87 ROE: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 88 ROE: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 89 ASIA-PACIFIC: IMMUNOASSAYS MARKET, BY COUNTRY, 2011 – 2018 ($MILLION)
TABLE 90 ASIA-PACIFIC: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 91 ASIA-PACIFIC: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 92 ASIA-PACIFIC: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 93 JAPAN: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 94 JAPAN: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 95 JAPAN: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 96 INDIA: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 97 INDIA: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 98 INDIA: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 99 CHINA: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 100 CHINA: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 101 CHINA: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 102 SOUTH KOREA: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 103 SOUTH KOREA: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 104 SOUTH KOREA: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 105 TAIWAN: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 106 TAIWAN: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 107 TAIWAN: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 108 ROAP: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 109 ROAP: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 110 ROAP: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 111 ROW: IMMUNOASSAYS MARKET, BY TECHNOLOGY, 2011 – 2018 ($MILLION)
TABLE 112 ROW: IMMUNOASSAYS MARKET, BY PRODUCT, 2011 – 2018 ($MILLION)
TABLE 113 ROW: IMMUNOASSAYS MARKET, BY APPLICATION, 2011 – 2018 ($MILLION)
TABLE 114 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, & JOINT VENTURES (2010 – 2013)
TABLE 115 NEW PRODUCT LAUNCHES (2010 – 2013)
TABLE 116 MERGERS & ACQUISITIONS (2010 – 2013)
TABLE 117 OTHER DEVELOPMENTS (2011 – 2013)
TABLE 118 APPENDIX: OTHER DEVELOPMENTS (2010 – 2013)
The major factors influencing the immunoassays market are increasing chronic diseases, increasing geriatric population, advancements in technology, the rise in the demand of portable point-of-care testing devices, and increasing healthcare spending from emerging countries.
The enzyme immunoassays segment accounted for the largest share of the global immunoassays market in 2012. This segment is expected to reach $XX million by 2018, at a CAGR of XX% from 2013 to 2018. This large share of enzyme immunoassays is attributed to their long-term market presence, high sensitivity in infectious/viral disease testing, and due to the huge demand from developing countries as they are manually operated and hence are available at lower costs than chemiluminescence immunoassays. However, the chemiluminescence immunoassays market will see the highest growth (CAGR of XX%) in the next five years as this market comprises of automated systems that offer the highest sensitivity.
The reagents segment accounted for the largest share of XX% of the immunoassays market in 2012. The accessibility of a wide range of reagents and the need for reliable, specific, and faster detection of chronic diseases at early stages are factors that are expected to drive the immunoassay reagents market.
Due to the economic slowdown and the Eurozone crisis, the economic situation worldwide is grim. Hence, it is predicted that analyzers and equipment buying will be delayed, at least for two years. However, automation and advancements in analyzers with high-throughput capacities are the major factors responsible for the growth of this market.
The key factors driving the growth of this segment include the rise in the development of drug dependent diagnostics and treatments, increasing need for drug content screening, and the large number of illicit drug users across the world. According to the National Survey on Drug Use and Health report, in 2011, XX million Americans aged 12 or above were illicit drug users. This represents XX% of the total population aged 12 or above.
The toxicology segment is expected to grow at a CAGR of XX% from 2013 to 2018 to reach $XX million by 2018. Roche Diagnostics Limited (Switzerland), Siemens Healthcare (Germany), Danaher Corporation (U.S.), Alere, Inc. (U.S.), and Ortho Clinical Diagnostics, Inc. (U.S.) are the key players involved in the manufacturing and marketing of drug testing devices, consumables, assays, and reagents.
